Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis.
Carter
Melody C
MC
Robyn
Jamie A
JA
Bressler
Peter B
PB
Walker
John C
JC
Shapiro
Gail G
GG
Metcalfe
Dean D
DD
D000293:Adolescent; D000707:Anaphylaxis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D008297:Male; D034721:Mastocytosis, Systemic / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008875:Middle Aged; D000069444:Omalizumab; D017455:Receptors, IgE / Q000037:antagonists & inhibitors; D014582:Urticaria Pigmentosa / Q000188:drug therapy / Q000276:immunology / Q000473:pathology
D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D017455:Receptors, IgE; D000069444:Omalizumab